Gloria Vittone Echeverria, Ph.D.
Picture
Gloria Vittone Echeverria, Ph.D.
Assistant Professor
Positions
- Assistant Professor
-
Baylor College of Medicine
Houston, Texas US
- CPRIT Scholar in Cancer Research
-
Cancer Prevention and Research Institute of Texas (CPRIT)
- Member
-
Lester and Sue Smith Breast Center
- Member
-
Dan L. Duncan Cancer Center
- Member
-
Department of Medicine
- Member
-
Department of Molecular and Cellular Biology
Addresses
- Office: R516 (Lab)
-
One Baylor Plaza
Houston, TX 77030
United States
gloria.echeverria@bcm.edu
Echeverria Lab website
- Office: R516 (Office)
-
One Baylor Plaza
Houston, TX 77030
United States
gloria.echeverria@bcm.edu
Echeverria Lab website
Education
- BS from Texas A&M University
- 05/2008 - College Station, Texas United States
- PhD from Baylor College of Medicine
- 10/2013 - Houston, Texas United States
- Postdoctoral Fellowship at The University of Texas MD Anderson Cancer Center
- 12/2019 - Houston, Texas United States
Professional Statement
The Echeverria laboratory studies the molecular evolution of triple negative breast cancer (TNBC) therapy resistance and metastasis. Cancers are ecosystems of diverse tumor and stroma cell subpopulations, each capable of contributing to tumor progression. While the existence of this complex intra-tumor heterogeneity has been well documented, its functional repercussions remain unclear. The focus of the lab is to delineate the metabolic and molecular evolution of TNBC using state-of-the art patient-derived xenograft mouse models and in vitro mouse- and patient-derived organoids. The lab utilizes functional genomics approaches, single-cell technologies, multiplexed tissue imaging, and metabolomics with the ultimate goal of combating tumor evolution to improve the lives of women living with TNBC.Websites
Selected Publications
- • Baek M, Lee JG, Pendleton KE, Berner MJ, Goff EB, Tan L, Martinez SA, Wang T, Meyer M, Lim B, Barrish JP, Lorenzi P, Porter W, Echeverria GV "Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment." 2023 Feb; Pubmed PMID: 36813854
- Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, et al. "Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state." Sci Transl Med. 2019; Pubmed PMID: 30996079
- Echeverria GV*, Cai S, Tu Y, Shao J, Powell E, Redwood A, Jiang Y, McCoy A, Rinkenbaugh A, Lau R, Trevarton A, Fu X, Gould R, Adrada B, Lane D, auch G, ang Q, Whie J, Chang JT, Moulder S, Symmans WF, Hilsenbeck SG, Piwnica-Worms H* "Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer from fine needle tumor aspirates." 2023; Pubmed PMID: 36627285
- Anurag M, Jaehnig E, Krug K, Lei JT, Bergstrom E, Kim BJ, Vashist T, Huynh A, Dou YU, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs R, Mani DR, Gilette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, and Ellis MJ "Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer." 2022; Pubmed PMID: 36001024
- Mavrommati I, Johnson F, Echeverria GV, Natrajan R "Modelling and targeting breast cancer heterogeneity- every cell counts.." 2021; Pubmed PMID: 34934048
- Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Tabue JH, Hollier BG, Ramirez-Pena EQ, Soundarajan R, den Hollander P, Powell E, Echeverria GV, et al. "Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth." Oncogene. 2016; Pubmed PMID: 27292262
- Baek M, Chang JT, Echeverria GV "Methodological advancements for investigating intra-tumoral heterogeneity in breast cancer at the bench and bedside." J Mammary Gland Biol Neoplasia. 2020 Dec 9; Pubmed PMID: 33300087
- Powell RT, Redwood A, Liu X, Gui L, Cai S, Zhou X, Tu Y, Qi Y, Jiang Y, Echeverria GV, Feng N, Ma X, Giuliani V, Marzalek JR, Heffernan TP, Vellano CR, Stephan C, Davies P, Chang JT, Moulder SL, Symmans WF, Piwnica-Worms H. "Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer.." Sci Reports. 2020 Oct 21; Pubmed PMID: 33087803
- Hsu T, Simon L, Heill N, Marcotte R, Sayad A, Bland C, Echeverria GV, et al. "The spliceosome is a therapeutic vulnerability in MYC-driven cancer.." Nature. 2015; Pubmed PMID: 26331541
- Powell E, Shao J, Yuan Y, Chen H, Cai S, Echeverria GV, et al. "p53 deficiency linked to BTG2 loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in PDX models of triple negative breast cancer.." Breast Cancer Res. 2016; Pubmed PMID: 26818199
- Roarty K, Echeverria GV "Laboratory models to study breast cancer therapy resistance and metastasis." Front Oncol. 2021 Mar 10;Doi: 10.3389/fonc.2021.645698.
- Echeverria GV, Powell E, Seth S, Ge Z, et al. "High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer.." Nat Commun. 2018; Pubmed PMID: 30498242
- • Stires H, Bado I, Brown T, Carlson M, Chan I, Echeverria GV, Ewald A, Lim B, Maues J, Oesterreich S, Riter B, Shanahan K, Newby J, Welm A "Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research." 2022; Pubmed PMID: 35773258
Funding
- R37 MERIT Award (12/22/2022 - 12/21/2025) Grant funding from NCI
- Research Scholar Grant (02/01/2023 - 01/31/2027) Grant funding from American Cancer Society
- First-Time Faculty Recruitment Award Grant funding from CPRIT
- SPORE Career Enhancement Program Award (08/01/2022 - 05/31/2023) Grant funding from NCI
Log In to edit your profile
